News
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
22 Jul 24
Analyst Color, Biotech, News, Health Care, Reiteration, Analyst Ratings, Movers, Trading Ideas, General
Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $220
22 Jul 24
News, Price Target, Analyst Ratings
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
18 Jul 24
News, Trading Ideas
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
17 Jul 24
Short Sellers, Short Ideas, Trading Ideas
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255
12 Jul 24
News, Price Target, Analyst Ratings
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $357
8 Jul 24
News, Price Target, Analyst Ratings
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
7 Jul 24
Biotech, Equities, Large Cap, Sector ETFs, Health Care, Small Cap, Global, Top Stories, Exclusives, Tech, ETFs
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
3 Jul 24
News, Trading Ideas
JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $248
3 Jul 24
News, Price Target, Analyst Ratings
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
14 Jun 24
News, Trading Ideas
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
13 Jun 24
News, Trading Ideas
Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
12 Jun 24
Options, Markets
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
17 May 24
Short Sellers, Short Ideas, Trading Ideas
10 Health Care Stocks With Whale Alerts In Today's Session
9 May 24
Options
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $400
7 May 24
News, Price Target, Analyst Ratings
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $225 Price Target
3 May 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target
2 May 24
News, Price Target, Reiteration, Analyst Ratings
Alnylam Pharmaceuticals Reiterats 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.4B-$1.5B
2 May 24
News, Guidance
Press releases
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
18 Jul 24
Press Releases
Alnylam Issues 2023 Corporate Responsibility Report
7 May 24
Press Releases
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2 May 24
Press Releases
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
30 Apr 24
Press Releases
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
30 Apr 24
Press Releases